AbCellera Biologics Inc. Share Price & Technical Analysis
ABCL · $5.42 (-3.56%)
Healthcare / Biotechnology
$5.42
-3.56%
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for …
Price chart
Seasonality
Jun has 2 positive and 3 negative years (last 5 years shown)
-11% return in Jun, 13% avg return in past 3 year Jun month.
62% return in 2026, -12% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 6% | 0% | 0% | 20% | 48% | -11% | – | – | – | – | – | – | 62% |
| 25 | 7% | -13% | -15% | 18% | -23% | 70% | 32% | 0% | 22% | 10% | -33% | -6% | 69% |
| 24 | -9% | -2% | -12% | -16% | 3% | -23% | 10% | -21% | 0% | 4% | 11% | -3% | -58% |
| 23 | 2% | -21% | -11% | -11% | 3% | -7% | 18% | -30% | -16% | -11% | 15% | 21% | -47% |
| 22 | -38% | -4% | 14% | -21% | 0% | 38% | -6% | 7% | -6% | 17% | 8% | -21% | -13% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.64B
P/E ratio
—
52W high
$6.79
52W low
$2.52
Volume
47,71,105
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹36,480
Abbott Laboratories Cede…
₹34,460
Eli Lilly And Company Ce…
₹30,560
Unitedhealth Group Inc C…
₹18,330
Elevance Health Inc
₹7,255
Frequently asked questions
- What is AbCellera Biologics Inc. share price today?
- AbCellera Biologics Inc. (ABCL) last traded around $5.42 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ABCL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ABCL. Download the app for real-time alerts.
- How can I analyze AbCellera Biologics Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.